Figure 1.
In vivo animal vaccination. Four vaccination groups were established: (1) PBS control, (2) dying myeloma cells-loaded dendritic cell (DC) vaccination, (3) pomalidomide + dexamethasone, and (4) DC vaccination + pomalidomide + dexamethasone. (A) Schematic representation of the combination of dendritic cells (DCs) + pomalidomide + dexamethasone. On day 0, MOPC-315 cells (5 × 105 per mouse) were injected subcutaneously into the right flank of BALB/c mice. After tumor growth, pomalidomide (0.06 mg/kg/day) was orally administered once a day for 25 days with a 3-day break after the first 11-day dosing period. Each dose of DCs (1 × 106 per mouse) was injected subcutaneously into the left flank of each BALB/c mouse in a volume of 0.1 mL PBS on days 11, 15, 25, and 29, and dexamethasone (0.6 mg/kg/day) was injected intravenously on days 10, 17, 24, and 3. (B) The data are means ± SEs and are representative of two independent experiments. The combination of DCs + pomalidomide + dexamethasone significantly inhibited tumor growth (*P < 0.05 on day 27) and induced a long-term systemic antimyeloma immune response (30 days).